PRINCETON, N.J.— 6월 20, 2023 — Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), today announced it has acquired Drug Interaction Solutions from the University of Washington. This transaction brings a world-renowned team of scientists and the Drug Interaction Database (“DIDB”), the leading subscription-based informatics solution for the identification of pharmacokinetic (PK) drug interactions, to Certara.
Used by over 200 Life Science companies and regulatory agencies, DIDB is the world’s largest curated database focusing on drug-drug interactions to support pharmaceutical scientists in their assessment of human PK-based drug interactions and drug safety. The addition of DIDB enhances Certara’s biosimulation platform by providing scientists an unbiased scientific library to support their decision-making process when evaluating drug interactions and drug safety.
“We are pleased to announce the acquisition of Drug Interaction Solutions,” said Patrick Smith, President of Certara Integrated Drug Development Consulting Services. “By incorporating the team and the databases into our business, we enhance our best-in-class scientific offering for our clients. This furthers Certara’s unique capabilities in the modelling and simulation of drug-drug interaction studies.”
DIDB originated at the University of Washington and was commercialized in 2002.
Certara 소개
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. 2,00062 Certara의 고객으로는 전 세계 62개국에 걸쳐 2,000개 이상의 글로벌 바이오 제약 회사, 선도적인 학술 기관 및 주요 규제기관들이 있다.
